-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
Healthcare AI Shakeout: Health Systems Plan to Cut AI Vendors Nearly in Half by 2028, Black Book Finds
-
Sparta Capital Ltd. Announces Resumption of Trading
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
CORRECTION FROM SOURCE: Nixxy Announces 1-for-20 Reverse Stock Split
-
Olenox Secures Texas Pipeline Operating Permit, Clearing Path for Initial 4 MW Power Deployment
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
Every month counts: European ALS patients want new drugs
Olivier Goy is running out of time.
The French entrepreneur was diagnosed in 2020 with amyotrophic lateral sclerosis (ALS) -- the incurable neurodegenerative disease that normally claims the lives of patients within three to five years.
There are new treatments that have given patients hope of being able to extend their lives by an invaluable few months, but the approval process in Europe is taking time, infuriating desperate patients.
"When you are certain to die soon, patients and some doctors are ready to take some risks," Goy told AFP.
In response to the lack of new treatments in his native France, the founder of the fintech start-up October spends 3,000 euros ($3,180) every month to buy the ingredients to make his own drugs.
ALS, also known as Lou Gehrig's disease, attacks the motor nerve cells in the brain and spinal cord, progressively paralysing muscles until patients cannot walk, eat, speak or breathe.
Around one in 10,000 people have the disease in the EU, according to the European Medicines Agency.
The drug Riluzole, which has been available in Europe and the UK since the 1990s, is capable of prolonging the lives of patients by around three months.
But otherwise, no new treatment has been approved in Europe for more than two decades.
- 'First hope in 20 years' -
A new treatment called AMX0035 was given the green light in the United States and Canada last year.
"It is the first hope we have had in 20 years: the first drug which is aimed at everyone and which had results" suggesting up to six months in added life expectancy, said Sabine Turgeman, head of the French Association for Research into ALS.
But the extent of the benefits of AMX0035 remains unclear. The US Food and Drug Administration approved the drug, sold under the name Relyvrio, based on the results of a single Phase 2 trial that involved just 137 participants.
The drug's developer, Amylyx Pharmaceuticals, is conducting larger, more comprehensive trials, with results expected in 2024.
Amylyx said earlier this month that the European Union's drug watchdog EMA is reviewing its submission for approval and it expects a decision in the first half of this year.
But for those with the disease, every delay represents a significant amount of the time they have left.
"It's not going fast enough," Turgeman said. "This disease is not on bureaucratic time".
For European patients who cannot afford to import their own ingredients like Goy, the only way to get access to new treatments is to join a clinical trial.
But such trials have very specific criteria for selection -- and even if a patient gets in, there is a chance they will be in the group given a placebo.
- 'Totally abandoned' -
Given how swiftly the disease progresses, patients and families are pressing for more options.
"We feel totally abandoned," said Sophie Garofalo, whose brother was diagnosed with ALS five years ago.
His family tried to enter him into clinical trials, "but either he does not meet the criteria, or the trials have already started," she said.
"He is ready to take anything, try everything".
French pharmaceutical company AB Science is developing another potential treatment using the drug masitinib, which initial results suggest could add months to the lives of patients.
The firm's CEO Alain Moussy said that because "time is very limited" for ALS patients, there should be more flexibility in the approval system.
"What degree of risk should be taken? That's for the health agencies to answer -- but they can guided by policymakers and patients," he said.
E.Rodriguez--AT